Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 49
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/23/2006
 
First Published:
4/1/2000
1.
Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprising Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
ECOG-4697
SWOG-E4697, E4697, NCT00005034
Last Modified:
6/8/2006
 
First Published:
5/1/2002
2.
Phase III Randomized Study of Adjuvant NA17-A and Melanoma Differentiation Peptides in HLA-A2-Positive Patients With Primary Ocular Melanoma at High Risk of Relapse
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Over 18
Other
EORTC-18001
EORTC-88001, NCT00036816
Last Modified:
8/10/2006
3.
Phase I/II Study of Immunization With Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigens MART-1 and gp100 With or Without Interleukin-2 in Patients With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
NCI
NCI-97-C-0046
NCI-97-C-0019, NCI-T96-0046N, T96-0046, NCT00019214
Last Modified:
5/17/2007
 
First Published:
4/1/1998
4.
Phase I/II Randomized Study of Antigen-Pulsed Autologous Dendritic Cells for Induction of Antitumor Immunity in Patients Completing Lymphadenectomy for Metastatic Melanoma (Summary Last Modified 05/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 to 75
NCI
DUMC-719975
DUMC-0932-99-5R2, DUMC-759-99-5R2, UVA-HIC-7454, NCI-G98-1398, NCT00003229
Last Modified:
7/1/2002
 
First Published:
2/1/2001
5.
Phase I/II Study of Ad2/MART-1v2 and Ad2/gp100v2 Melanoma Antigen Vaccines in Patients With Stage II, III, or IV Melanoma (Summary Last Modified 07/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
GENZ-ADVMEL-001-99
DFCI-00069, GENZ-2000-P-000380/1, NCT00010309
Last Modified:
7/1/2008
 
First Published:
5/28/2004
6.
Phase I/II Pilot Study of a Multi-Epitope Peptide Vaccine With Sargramostim (GM-CSF) Plasmid DNA Immune Adjuvant in Patients With Stage IIB, IIC, III, or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
Any age (weight > 25 kg)
NCI
MSKCC-00142A
5906, NCI-5906, NCT00085137
Last Modified:
8/31/2006
 
First Published:
1/1/1998
7.
Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
16 and over
NCI
NCI-98-C-0023
NCI-T97-0089, T97-0089
Last Modified:
9/1/2002
 
First Published:
3/1/1998
8.
Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
Not specified
NCI
NCI-98-C-0040
NCI-T97-0092, T97-0092, NCT00019396
Last Modified:
4/1/2002
 
First Published:
4/1/1998
9.
Phase II Study of Vaccination with Synthetic Melanoma Peptide Administered with Sargramostin (GM-CSF) Plus Interleukin-2 in Patients with Advanced Melanoma (Summary Last Modified 04/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18-79
NCI
UVACC-HIC-7621
UVA-HIC-7621, NCI-G98-1389, NCT00003222
Last Modified:
5/17/2007
 
First Published:
8/1/1999
10.
Phase II Randomized Study of Vaccine Comprising Tyrosinase Peptide and gp100 Antigen With Montanide ISA-51 Alone or With Sargramostim (GM-CSF) in Patients with Resectable Stage IIA or IIB Melanoma (Summary Last Modified 11/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
LAC-USC-10M971
LAC-USC-FDR001101, NCI-T97-0100, NCT00003274, T97-0100
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute